While LifeStance Health (NASDAQ: LFST) has increased its revenue year over year, it is still taking a measured approach to growth.
The provider continued its M&A pause in Q3. Instead, it is looking at de novo growth and organizing its assets – at least for now.
LifeStance has opened 8 de novo facilities in Q3 and 23 this year. Meanwhile, it had no new acquisitions in Q3 and no plans for the rest of the year.
But the organization faces a number of challenges as well. LifeStance no longer plans to end the year cash flow positive, as it digs out of a shareholder class action lawsuit settlement, Behavioral Health Business reports. Read more.
